参考文献/References:
[1]Rudd KE,Johnson SC,Agesa KM,et al.Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J].Lancet,2020,395(10219):200-211.[2]Srziｃ I,Nesek AV,Tunjiｃ PD.Sepsis Definition: What’s New ?In The Treatment Guidelines[J].Acta Clin Croat,2022,61(Suppl 1):67-72.[3]Wang Z,Rui T,Yang M,et al.Alveolar macrophages from septic mice promote polymorphonuclear leukocyte transendothelial migration via an endothelial cell Src kinase/NADPH oxidase pathway[J].J Immunol,2008,181(12):8735-8744.[4]Kumar V.Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury[J].Front Immunol,2020,11:1722.[5]Howrylak JA,Dolinay T,Lucht L,et al.Discovery of the gene signature for acute lung injury in patients with sepsis[J].Physiol Genomics,2009,37(2):133-139.[6]Wang YM,Qi X,Gong FC,et al.Protective and predictive role of Mucin1 in sepsis-induced ALI/ARDS[J].Int Immunopharmacol,2020,83:106438.[7]Rego SM,Snyder MP.High Throughput Sequencing and Assessing Disease Risk[J].Cold Spring Harb Perspect Med,2019,9(1):a026849.[8]Oliver GR,Hart SN,Klee EW.Bioinformatics for clinical next generation sequencing[J].Clin Chem,2015,61(1):124-135.[9]Ho P,Clark IM,Le LTT.MicroRNA-Based Diagnosis and Therapy[J].Int J Mol Sci,2022,23(13):7167.[10]Bone RC,Balk RA,Cerra FB,et al.definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J].Crit Care Med,1992,20(6):864-874.[11]Bernard GR,Artigas A,Brigham KL,et al.The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination[J].Am J Respir Crit Care Med,1994,149(3 Pt 1):818-824.[12]Szklarczyk D,Gable AL,Nastou KC,et al.The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J].Nucleic Acids Res,2021,49(D1):D605-D612.[13]Pripp AH.Pearson’s or Spearman’s correlation coefficients[J].Tidsskr Nor Laegeforen,2018,138(8).[14]Huang HY,Lin YC,Cui S,et al.miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions[J].Nucleic Acids Res,2022,50(D1):D222-D230.[15]Tibshirani R.The lasso method for variable selection in the Cox model[J].Stat Med,1997,16(4):385-395.[16]Chen L,Heikkinen L,Wang C,et al.Trends in the development of miRNA bioinformatics tools[J].Brief Bioinform,2019,20(5):1836-1852.[17]Li S,Han F,Qi N,et al.Determination of a six-gene prognostic model for cervical cancer based on WGCNA combined with LASSO and Cox-PH analysis[J].World J Surg Oncol,2021,19(1):277.[18]Fan E,Fan J.Regulation of alveolar macrophage death in acute lung inflammation[J].Respir Res,2018,19(1):50.[19]Guerrero-Fonseca IM,García-Ponce A,Vadillo E,et al.HS1 deficiency protects against sepsis by attenuating neutrophil-inflicted lung damage[J].Eur J Cell Biol,2022,101(2):151214.[20]Abbas T,Dutta A.p21 in cancer: intricate networks and multiple activities[J].Nat Rev Cancer,2009,9(6):400-414.[21]Kreis NN,Louwen F,Yuan J.Less understood issues: p21(Cip1) in mitosis and its therapeutic potential[J].Oncogene,2015,34(14):1758-1767.[22]Romanov VS,Rudolph KL.p21 shapes cancer evolution[J].Nat Cell Biol,2016,18(7):722-724.[23]Waga S,Hannon GJ,Beach D,et al.The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA[J].Nature,1994,369(6481):574-578.[24]Yang D,Yan Y,Hu F,et al.CYP1B1, VEGFA, BCL2, and CDKN1A Affect the Development of Chronic Obstructive Pulmonary Disease[J].Int J Chron Obstruct Pulmon Dis,2020,15:167-175.[25]Yang J,Zhang MY,Du YM,et al.Identification and Validation of CDKN1A and HDAC1 as Senescence-Related Hub Genes in Chronic Obstructive Pulmonary Disease[J].Int J Chron Obstruct Pulmon Dis,2022,17:1811-1825.[26]Fan J,Chen M,Cao S,et al.Identification of a ferroptosis-related gene pair biomarker with immune infiltration landscapes in ischemic stroke: a bioinformatics-based comprehensive study[J].BMC Genomics,2022,23(1):59.[27]Tarangelo A,Magtanong L,Bieging-Rolett KT,et al.p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells[J].Cell Rep,2018,22(3):569-575.[28]Chen R,Cao J,Jiang W,et al.Upregulated Expression of CYBRD1 Predicts Poor Prognosis of Patients with Ovarian Cancer[J].J Oncol,2021,2021:7548406.[29]Gao XL,Li JQ,Dong YT,et al.Upregulation of microRNA-335-5p reduces inflammatory responses by inhibiting FASN through the activation of AMPK/ULK1 signaling pathway in a septic mouse model[J].Cytokine,2018,110:466-478.[30]Zhang Z,Chen L,Xu P,et al.Gene correlation network analysis to identify regulatory factors in sepsis[J].J Transl Med,2020,18(1):381.[31]Liang Q,He J,Yang Q,et al.MicroRNA-335-5p alleviates inflammatory response, airway fibrosis, and autophagy in childhood asthma through targeted regulation of autophagy related 5[J].Bioengineered,2022,13(1):1791-1801.[32]Sun D,Ma T,Zhang Y,et al.Overexpressed miR-335-5p reduces atherosclerotic vulnerable plaque formation in acute coronary syndrome[J].J Clin Lab Anal,2021,35(2):e23608.[33]Lu W,Ma YY,Shao QQ,et al.ROS/p53/miR-335-5p/Sp1 axis modulates the migration and epithelial to mesenchymal transition of JEG-3 cells[J].Mol Med Rep,2020,21(3):1208-1216.[34]Gu X,Yao X,Liu D.Up-regulation of microRNA-335-5p reduces inflammation via negative regulation of the TPX2-mediated AKT/GSK3β signaling pathway in a chronic rhinosinusitis mouse model[J].Cell Signal,2020,70:109596.[35]Kang Z,Zhu J,Sun N,et al.COL11A1 promotes esophageal squamous cell carcinoma proliferation and metastasis and is inversely regulated by miR-335-5p[J].Ann Transl Med,2021,9(20):1577.[36]Li J,Feng Z,Chen L,et al.MicroRNA-335-5p inhibits osteoblast apoptosis induced by high glucose[J].Mol Med Rep,2016,13(5):4108-4112.
相似文献/References:
[1]杨 雍,吕汝琦,刘 丹.早期无创正压通气对重症急性胰腺炎合并肺损伤的保护作用机制[J].医学信息,2019,32(03):55.[doi:10.3969/j.issn.1006-1959.2019.03.018]
YANG Yong,LV Ru-qi,LIU Dan.Protective Mechanism of Early Noninvasive Positive Pressure Ventilation on Severe Acute Pancreatitis Complicated with Lung Injury[J].Journal of Medical Information,2019,32(16):55.[doi:10.3969/j.issn.1006-1959.2019.03.018]
[2]申 贵,彭 翔,秦光梅.抗感染督导治疗对脓毒症患者预后影响的研究[J].医学信息,2019,32(01):82.[doi:10.3969/j.issn.1006-1959.2019.01.026]
SHEN Gui,PENG Xiang,QIN Guang-mei.Study on the Effect of Anti-infective Supervision on the Prognosis of Patients with Sepsis[J].Journal of Medical Information,2019,32(16):82.[doi:10.3969/j.issn.1006-1959.2019.01.026]
[3]张恺悦,陈幼琼.乌司他丁联合血必净对烧伤后脓毒症患者凝血功能及全身炎性反应的影响研究[J].医学信息,2019,32(04):138.[doi:10.3969/j.issn.1006-1959.2019.04.044]
ZHANG Kai-yue,CHEN You-qiong.Effect of Ulinastatin Combined with Xuebijing on Coagulation Function and Systemic Inflammatory Response in Patients with Sepsis after Burn[J].Journal of Medical Information,2019,32(16):138.[doi:10.3969/j.issn.1006-1959.2019.04.044]
[4]张文旭,徐 绸.红细胞宽度对脓毒症患者病情诊断及预后评估的价值[J].医学信息,2022,35(14):71.[doi:10.3969/j.issn.1006-1959.2022.14.015]
ZHANG Wen-xu,XU Chou.The Value of Red-blood-cell Distribution Width in the Diagnosis and Prognosis of Patients with Sepsis[J].Journal of Medical Information,2022,35(16):71.[doi:10.3969/j.issn.1006-1959.2022.14.015]
[5]朱思哲,叶成林.基于生物信息学分析构建免疫相关基因脓毒症预后模型[J].医学信息,2022,35(15):1.[doi:10.3969/j.issn.1006-1959.2022.15.001]
ZHU Si-zhe,YE Cheng-lin.Identification of Immune-related Gene Prognostic Model for Sepsis Based on Bioinformatics Analysis[J].Journal of Medical Information,2022,35(16):1.[doi:10.3969/j.issn.1006-1959.2022.15.001]
[6]杨勋能.参苓白术散对脓毒症患者肠道功能的影响[J].医学信息,2019,32(16):146.[doi:10.3969/j.issn.1006-1959.2019.16.049]
YANG Xun-neng.Effect of Shenling Baizhu Powder on Intestinal Function in Patients with Sepsis[J].Journal of Medical Information,2019,32(16):146.[doi:10.3969/j.issn.1006-1959.2019.16.049]
[7]杜金洁,胡 鹏.ESKAPE病原菌感染引起脓毒症的研究[J].医学信息,2019,32(21):33.[doi:10.3969/j.issn.1006-1959.2019.21.012]
DU Jin-jie,HU Peng.Study on Sepsis Caused by ESKAPE Pathogen Infection[J].Journal of Medical Information,2019,32(16):33.[doi:10.3969/j.issn.1006-1959.2019.21.012]
[8]刘安平,段海真,汪 松.抗菌肽LL-37的生物学活性及其作用[J].医学信息,2019,32(24):13.[doi:10.3969/j.issn.1006-1959.2019.24.005]
LIU An-ping,DUAN Hai-zhen,WANG Song.Biological Activity and Effect of Antibacterial Peptide LL-37[J].Journal of Medical Information,2019,32(16):13.[doi:10.3969/j.issn.1006-1959.2019.24.005]
[9]陈冀远.右美托咪啶对脓毒症急性肾损伤患者肾功能及血管紧张素Ⅱ表达的影响[J].医学信息,2020,33(01):142.[doi:10.3969/j.issn.1006-1959.2020.01.045]
CHEN Ji-yuan.Effect of Dexmedetomidine on Renal Function and Angiotensin Ⅱ Expression in Patients with Acute Renal Injury in Sepsis[J].Journal of Medical Information,2020,33(16):142.[doi:10.3969/j.issn.1006-1959.2020.01.045]
[10]赵振宇.miR-33表达与炎症反应的关系[J].医学信息,2020,33(02):73.[doi:10.3969/j.issn.1006-1959.2020.02.020]
ZHAO Zhen-yu.Relationship Between miR-33 Expression and Inflammatory Response[J].Journal of Medical Information,2020,33(16):73.[doi:10.3969/j.issn.1006-1959.2020.02.020]
[11]温占兵.血管生成素-1水平变化预测脓毒症急性肺损伤的价值[J].医学信息,2018,31(13):95.[doi:10.3969/j.issn.1006-1959.2018.13.027]
WEN Zhan-bing.The Value of Angiopoietin-1 Level Change in Predicting Acute Lung Injury in Sepsis[J].Journal of Medical Information,2018,31(16):95.[doi:10.3969/j.issn.1006-1959.2018.13.027]